Sildenafil Efficacy Study on Time Walk From Peripheral Arterial Desease Patients (Stade II) With Arterial Claudication
- Conditions
- Peripheral Arterial Occlusive Disease
- Interventions
- Drug: Placebo, Oral intake single dose
- Registration Number
- NCT02832570
- Lead Sponsor
- University Hospital, Angers
- Brief Summary
Efffect of a single dose oral intake of sildenafil Or placebo on the walking capacity on treadmill of PAD patients with claudication
- Detailed Description
Sildenafil 100mg or Placebo Oral intake 2 hours before the treadmill test Safety and security control throughout the period of drug efficacy (approx 4 hours) Evaluation of maximal walking distance for a constant load treadmill test (3.2 kml/h 10% slope)
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
- Patient with peripheral arterial desease stade II
- Patient with vascular claudication for at least 3 months
- Patient able to perform a treadmill walking test with time to walk < 5min
- Patient suffering from ischemia
- Previous angina or myocardial
- Patient treated with nitrates drugs
- Patient with severe renal insufficiency
- Patient with severe hepatic insufficiency
- Patient with hypotension
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo Placebo, Oral intake single dose Single placebo intake approximately 2 hours before the treadmill test. Sildenafil Sildenafil 100mg single oral dose Single sildenafil oral intake (100 mg) approximately 2 hours before the treadmill test.
- Primary Outcome Measures
Name Time Method Walking duration on treadmill 2 hours after treatment intake Treadmill test with consttant load procedure 3.2 km/h H 10% slope up to 15 minutes followed by incremental load according tpo the Bruce protocole thereafter.
- Secondary Outcome Measures
Name Time Method